IMR Press / FBL / Volume 14 / Issue 9 / DOI: 10.2741/3452

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Proteomics strategies for target identification and biomarker discovery in cancer
Show Less
1 Norlux Neuro-Oncology Laboratory, CRP-Sante, 84, Val Fleuri, L-1526 Luxembourg, Luxembourg
2 OncoProteomics Laboratory, VUmc-Cancer Center Amsterdam, VU University Medical Center, De Boelelaan 1081, Amsterdam, The Netherlands

Academic Editor: Rolf Bjerkvig

Front. Biosci. (Landmark Ed) 2009, 14(9), 3292–3303; https://doi.org/10.2741/3452
Published: 1 January 2009
(This article belongs to the Special Issue Tumor angiogenesis and molecular targets)
Abstract

The revolution in genomics and proteomics has produced complex technologies enabling an insight into the functional effectors of cellular processes. In oncology these technologies lead to the identification of biological markers which may provide the starting point for the development and identification of diagnostic tests and therapeutic targets. To identify and validate reliable tumor markers within the proteome, it is necessary, prior to tandem mass spectrometry, to reduce sample complexity. This can be done by robust fractionation and separation techniques. This review addresses the discovery stage of onco-proteomics - the strategies for target identification and biomarker discovery in solid tumors and biofluids. The overview includes different proteomic methods, from gel-based to liquid chromatography (LC)-based separations of proteins/peptides, and the corresponding detection by mass spectrometry. The quantitative methods in mass spectrometry include techniques based on stable isotope labeling of proteins/peptides and label-free methods. A particular emphasis is given to proteomics-based biomarker discovery in biofluids (e.g. plasma, urine, secretome, cerebrospinal fluid) and target identification in tissue for anti-angiogenic therapies.

Share
Back to top